Assessment of gene signatures following the inhibition of IL-23: a study to evaluate the mechanistic effects behind the clinical efficacy of guselkumab in patients with psoriatic arthritis.

ABSTRACT:

Objectives

The aim of this study was to evaluate the transcriptome of peripheral blood mononuclear cells (PBMCs) derived from patients affected by psoriasis (PSO) and psoriatic arthritis (PSA) following treatment with guselkumab, an interleukin (IL)-23 inhibitor.

Methods

mRNA was extracted by PBMCs, before and after 24 weeks of treatment with guselkumab, and RNA sequencing was performed in paired-end mode by Illumina technology using the Novaseq6000 platform. log2FoldChange > 1 and p _adj < 0.05 were the established cutoff to discriminate genes differentially expressed between pre- and post-therapy. For annotation and predictive enrichment analysis of deregulated genes in biological pathways, RStudio was used, and Gene Ontology (GO) and Kyoto Encyclopedia of

SUBMITTER: Mastrangelo M 

PROVIDER: S-EPMC12436422 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature